Volume 16 Issue 1, March 2022

Using an aptamer-based approach, SomaLogic can identify up to 7,000 proteins at high levels of specificity, providing real-time precision proteomics for use in the lab and the clinic.

Source BioScience is a leading provider of laboratory services to blue chip biopharma, the UK’s National Health Service, and private hospitals. With global operations expanding in the UK, Ireland, and USA, Source is seeking partners for its analytical and diagnostic services.

Seattle’s SEngine is using patient tumor samples to derive cancer organoids for accurate ex vivo drug testing, target identification and drug development.

With its Oncobiota platform, Micronoma is pioneering the analysis of the cancer microbiome for early cancer detection and creating tools for personalized cancer treatment.

Foresight Diagnostics has developed a platform that detects circulating tumor DNA at levels below one part-per-million, allowing accurate identification of minimal residual disease well below current levels of detection. With testing available for B cell lymphomas and solid tumors, Foresight offers partnering opportunities ranging from investigational through prospective clinical studies and companion diagnostic development.

Karius is helping doctors identify infections early among the most vulnerable patients, redrawing the liquid biopsy space along the way.

Based on novel microfluidic chip technology, Lunaphore’s COMET platform will enable spatial biology in every lab.

TransCode Therapeutics has developed an iron oxide nanoparticle–based therapeutic RNA delivery system that maximizes targeted tumor uptake while minimizing clearance. With a lead candidate in metastasis and several preclinical programs targeting other cancers, the company is rapidly expanding its portfolio.

Indivumed is committed to the advancement of precision oncology solutions by harnessing deep multi-omics data from its highly standardized proprietary tissue bank, bioinformatics and artificial intelligence-integrated advanced data analytics.

Kinomica uses its cutting-edge phosphoproteomics platform KScan to identify molecular signatures predictive of drug response in clinical samples.

RNA-based complementary and companion diagnostics could identify more patients able to receive clinical benefit from cancer therapeutics and increase response rates. Employing its expertise in RNA gene signatures, GeneCentric is developing these novel diagnostics through strategic partnerships with biopharma and diagnostics companies.

Octave has developed a first-in-class, fully integrated comprehensive Precision Care Solution for the personalized treatment of multiple sclerosis and other neurodegenerative diseases.

ExosomeDx, together with its parent company Bio-Techne, combines expertise in exosome technologies with experience in the non-invasive liquid biopsy market to create solutions for companion diagnostic development and biopharmaceutical services.

Oncology-focused partnerships drove record-level licensing deals in 2021 as companies looked to gain access to novel therapeutic targets and platforms.

POINT Biopharma is a late-stage precision oncology company, focused on developing and bringing to market next generation radioligand therapies. These therapies are like microscopic, cancer-seeking missiles, that precisely deliver radiation to tumors, against a range of cancers.

With a focus on detecting, intercepting, treating, and ultimately curing cancer, Janssen Oncology is advancing science and solutions in hematologic malignancies and solid tumors through an innovative strategic partnering approach.

A highly sensitive, multi-analyte blood test from Helio Health points to earlier detection of hepatocellular carcinoma and shows promise for a future of widely accessible cancer detection.

Priothera’s small molecule mocravimod is transforming the prospects of patients with hematological malignancies receiving hematopoietic stem cell transplants.

Ellipses Pharma has implemented a disruptive approach to cancer drug development that greatly accelerates the delivery of novel solutions for patients. With seven lead products and a growing pipeline of assets, the company is planning to have a first drug ready for out-licensing in 2024.

With a lead candidate harnessing antibody-driven cytotoxic mechanisms to drive tumor cell death, Byondis is developing a pipeline of candidates targeting oncology by combining its unrivaled expertise in linker-drug technology, antibody–drug conjugation, targeted cytotoxic therapy and the development of monoclonal antibodies.

PanTher Therapeutics is targeting solid tumors through direct, localized, and sustained delivery of therapeutic agents. The company’s lead program is in a phase 1 trial, and the company is seeking partners to further develop its platform.

Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.

TargImmune is developing first-in-class targeted apoptotic immune modulators (TAIMs) based on the Ta:RNA technology platform which mimics viral infection by selectively delivering viral-like double-stranded RNA to tumor cells and harnessing the body’s antiviral defence mechanism against cancer.

Using a suite of proprietary components, Vincerx Pharma has created a tuneable, modular platform to develop a new generation of novel conjugated cancer therapies with improved safety and efficacy.

The Danish biotech company MonTa Biosciences has developed a novel immunotherapeutic nanoparticle that is currently in a phase 1 clinical trial in patients with solid tumors.

With its unique multi-targeted T cell-based immunotherapies that simultaneously attack tumors and trigger a broad spectrum antitumor immune response, Marker has generated promising clinical data in more than 150 patients in both hematological malignancies and solid tumors.

Using its proprietary nanodelivery technology, Libera Bio is bringing biologics such as monoclonal antibodies to intracellular oncology targets.

Rubius Therapeutics is biologically engineering red blood cells to provide a new class of off-the-shelf cellular therapies for cancer and autoimmune diseases. Three of its product candidates, RTX-240, RTX-224 and RTX-321 are progressing through phase 1 clinical trials for advanced cancers.

Aiding the immune response in the fight against cancer, TILT Biotherapeutics is developing armed oncolytic viruses that replicate in cancer cells making them more discoverable by T cells and other immunotherapies.

Following its success in the veterinary market, QBiotics is now developing tigilanol tiglate for use against solid tumors in humans via intratumoral injection.

Chordia Therapeutics is developing small-molecule anticancer drugs with novel mechanisms of action and a focus on inducing stress overload in RNA deregulation.